#7 - Merck & Co. (NYSE:MRK)
It’s been a good year for biopharmaceutical companies that offer GLP-1 drugs. That’s left companies like Merck & Co. (NYSE: MRK) on the wrong side of the biopharma trade. The stock is down about 7.6% in 2024.
The concern is not about the company’s current performance—it continues to post YoY gains on the top and bottom lines. But investors are concerned about the patent cliff for the company’s blockbuster drug Keytruda, which will occur in 2028. Keytruda currently accounts for about 50% of the company’s revenue, and while the company has a deep pipeline, there’s no immediate replacement for Keytruda.
Nevertheless, some analysts believe that the company’s revenue recovery may be good enough. The consensus price target of $129.20 gives the stock a 28.4% upside, and investors also get a dividend with an attractive 3.08% yield.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More - Current Price
- $99.34
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $124.00 (24.8% Upside)
Analysis paralysis is one of the biggest impediments for investors to overcome. It's one thing to decide that you have to make changes to your portfolio. But it can be difficult to decide what those changes should be, particularly when you're considering your investment goals and risk tolerance.
You can put your money into ETFs. But if you're reading this presentation, we suspect you have the time and the interest in picking your own stocks.
MarketBeat has several tools to help simplify the process of finding investment ideas. To find the stocks in this presentation, we used the MarketBeat Stock Screener and adjusted the filters to find stocks trading within 30% of their 52-week lows but with at least 10% earnings upside for 2024.
And that's just one free tool available to investors. MarketBeat All-Access members can take advantage of the MarketBeat Idea Engine, which uses over two dozen algorithmic factors and technical indicators to identify stocks signaling near-term growth.
More Investing Slideshows:
